The 9–11 mg band is the strongest tier the United States allows and the exact point where Denmark stops — and “9 mg” means at least four different quantities depending on whose can it is printed on. Thirteen US-authorised products sit at 9 mg, one at 11 mg, and the regulator that authorised them says in the same breath that the label does not determine the dose.
Something odd happened to this tier in 2026. On 21 August the FDA authorised eleven new nicotine pouch products, ten at 9 mg and one at 11 mg, and the strongest pouches legally sold in the United States went from 6 mg to 11 mg overnight. In Denmark, meanwhile, 9.0 mg per pouch has been the legal ceiling since 1 July 2025, and the market leader’s own strength ladder has visibly collapsed against it. Same band, opposite treatment, both from regulators reading the same science.
If you are coming at this from below, the 6 mg tier is the sensible place to start, and the full mg guide covers the whole ladder.
What is actually in the 9–11 mg band
In the United States the answer is exact, because the FDA publishes the complete list of what may lawfully be sold. As of content current 21 August 2026, that list holds 43 products from two companies — Helix Innovations LLC and Swedish Match USA, Inc. — and FDA’s wording is unambiguous: “These are the only nicotine pouch products that may be lawfully sold in the United States.”
Inside the band:
| Strength | Products | Company |
|---|---|---|
| 9 mg | ZYN ULTRA Chill, Citrus, Cool Mint, Deep Freeze, Menthol, Peppermint, Smooth, Spearmint, Wintergreen, Wintergreen Chill | Swedish Match USA |
| 9 mg | on! PLUS Mint, Tobacco, Wintergreen | Helix Innovations |
| 11 mg | ZYN ULTRA Smooth | Swedish Match USA |
Two details worth having right. 9 mg is not a ZYN monopoly — Altria’s Helix subsidiary is authorised at 9 mg too, so both US-authorised companies sell into this tier. And 11 mg exists in exactly one flavour, ULTRA Smooth, which is also sold at 9 mg: one 11 mg product in the United States, not eleven.
The distinct strengths on the whole authorised list are 2, 3, 4, 6, 9 and 11 mg. There is no 5, no 7, no 8, no 10. The gap between 6 and 9 is the widest step on the American ladder, and there is nothing in between to break the jump.
Outside the United States the band is populated differently. Nordic Spirit sells 9 mg as “Strong” and 11 mg as “X-Strong”, with 17 mg above them. ZYN’s UK range runs 9 mg, 11 mg, 13.5 mg and 16.5 mg — so the product the US calls ULTRA and treats as its ceiling is a mid-table entry in Britain. VELO’s US line reaches 9 mg in VELO PLUS and 12 mg in VELO MAX, neither of which is on the FDA list. And Rogue, a brand with a reputation for strength, does not enter the band at all: its entire published range is 3 mg and 6 mg.
“9 mg” means at least four different things
This is not niche pedantry — a German federal regulator has written it up as a consumer-protection problem. A pouch’s nicotine can be stated per pouch or per gram of contents, and Nordic Spirit is the only brand I have found that publishes both bases across its whole range:
| Nordic Spirit tier | Per pouch | Per gram |
|---|---|---|
| Regular, mini | 3 mg | 9 mg/g |
| Mellow, mini | 4 mg | 9 mg/g |
| Regular, standard | 6 mg | 9 mg/g |
| Strong, standard | 9 mg | 14 mg/g |
| X-Strong, standard | 11 mg | 17 mg/g |
| Max, standard | 17 mg | 24 mg/g |
Read that table twice. On one manufacturer’s own figures, “9 mg” denotes 3, 4, 6 or 9 mg of nicotine depending on which basis you are reading and which format you are holding. A ZYN ULTRA “9 mg” is per pouch; a Nordic Spirit “9 mg per gram” is a 3–6 mg pouch. Same two characters, threefold difference.
Germany’s Federal Institute for Risk Assessment (BfR) found exactly this in a market sample and said so in its published opinion: “Nicotine content, expressed as mg per pouch or per g, was declared clearly on only about a third of the nicotine pouches examined.” On the descriptive words brands use instead, it found “a lot of overlap, rendering a clear differentiation difficult.” And on the cause:
“One reason could be that some manufacturers meant the nicotine content per pouch and others per gram.” “However, this fact is not apparent to the consumer.” “Switching between products from different manufacturers can result in nicotine content per pouch doubling”
A regulator quantifying the trap as a doubling is as good as this gets. It is also worth noting who states the basis and who does not. VELO’s US FAQ says “per pouch” explicitly. VELO Denmark prints “9 mg nikotin pr. pose”. ZYN’s US FAQ says ULTRA “come in 9 mg and 11 mg strengths” and never says per what — it uses “per pouch” only for sodium and carbohydrate. Nor does ZYN publish an ULTRA pouch mass: the 0.4 g figure on its FAQ is given for “One ZYN pouch”, and ULTRA comes 20 to a can against the classic 15, so it is plausibly a different format. There is no published way to convert an ULTRA strength to mg/g. The two bases deserve their own guide, and they have one.
BfR also noticed something in 2022 that reads differently in hindsight. Listing the “figurative language” brands use for strength, it named “‘easy’, ‘medium’, ‘strong’, ‘extra strong’, ‘ultra’, ‘extreme’, ‘danger strong’ or ‘brutal'”, and reported that products in the above-extra-strong group “ranged from 12.1 mg per pouch (product described as ‘ultra’) to 47.5 mg per pouch (product described as ‘brutal’)”. A European regulator was treating “ultra” as a super-strength descriptor four years before the FDA authorised a product line called ULTRA at 9 and 11 mg.
Denmark: where 9 mg is the ceiling and 11 mg is illegal
Denmark is the clearest demonstration of what a per-pouch cap does to a market, and the instrument is three sections long. Bekendtgørelse nr. 249 af 4. marts 2025, made under § 10 a, stk. 2 of the Danish Tobacco Act, defines a nicotine pouch at § 1 as an orally taken tobacco surrogate “i portionsbreve eller porøse breve” — in portion sachets or porous sachets. Section 2 then does the whole job in one sentence: “Nikotinposer må maksimalt indeholde 9,0 mg nikotin pr. pose.” Nicotine pouches may contain a maximum of 9.0 mg of nicotine per pouch. Section 3: “Bekendtgørelsen træder i kraft den 1. juli 2025.”
Not mg per gram. Per pouch — the unit that cannot be gamed by making the pouch heavier. What that looks like on a shelf is unusually visible. VELO Denmark — British American Tobacco Denmark A/S — lists 21 products, and the complete set of per-pouch values across all of them is 4, 6, 8 and 9 mg. Nine products sit at exactly 9 mg, pinned to the statutory ceiling.
And the brand’s own strength legend is a fossil of the market before the cap. The legend printed on that page maps strength levels to milligrams like this: “1 4 MG 2 6 MG 3 8 mg & 10 MG 4 10.9 MG 5 14 MG”. Level 4 is advertised as 10.9 mg. Level 5 is advertised as 14 mg. Every level-4 and level-5 product actually on sale in Denmark is 9 mg — including one listed as “Styrkeniveau: 5 (9mg/pouch)” beneath a legend that says level 5 means 14 MG. Three tiers have been compressed onto one number by law, and the signage has not caught up.
Across the border, the same brand in Sweden — no cap at all — sells at 6, 8, 10, 12.5 and 14 mg. One owner, one brand, two markets, a 14 mg ladder on one side of the Øresund and a 9 mg wall on the other. ZYN ULTRA Smooth at 11 mg, lawful in the United States, could not lawfully be sold in Denmark.
The caps, and the units they are written in
| Jurisdiction | Limit | Unit | Instrument |
|---|---|---|---|
| Denmark | 9.0 mg | per pouch | BEK nr. 249 af 04/03/2025 § 2; in force 1 July 2025 |
| Czechia | 12 mg per dose, 240 mg per pack, minimum 20 doses | per dose and per pack | Vyhláška 141/2023 Sb. § 2(4)–(5); in force 1 July 2023 |
| Poland | 20 mg/g | per gram | Dz.U. 2025 poz. 799, art. 11hb ust. 1 pkt 1 |
| Finland | 16.6 mg/g | per gram | Notified to the EU as TRIS 2024/0643/FI |
| Sweden | none | — | no nicotine figure in lag (2022:1257) |
| United Kingdom | none in force | — | power at Tobacco and Vapes Act 2026 c.18 s.96, unexercised |
| United States | no cap; authorised list tops out at 11 mg | per pouch | FDA premarket authorisation |
Czechia is the counterpoint: 12 mg per dose, a 240 mg ceiling on the pack and a minimum of 20 doses in it, which makes the two limits exactly consistent. It is the one place in this table where the whole 9–11 mg band fits under the cap with room above.
Poland’s drafting carries its own version of the units problem. The statute says the nicotine content “w woreczku nikotynowym” — in the nicotine pouch — and then gives the unit as mg/g. Per-pouch phrasing, per-gram unit, in the enacted law. The confusion is not only on the cans.
The European Union sets nothing, for a structural reason rather than a policy one: the Tobacco Products Directive reaches products “made wholly or partly of tobacco”, and a tobacco-free pouch is not. The regulation tracker follows the rest.
Does a 9 mg pouch deliver 9 mg? No — and the FDA says so itself
The clearest statement of the answer comes from the regulator that authorised the tier, in the announcement doing so:
“Nicotine exposure is influenced not only by a product’s labeled nicotine content” “but also by its design, formulation, materials, and other characteristics”
That is FDA, 21 August 2026, on the same page that announced the 9 and 11 mg authorisations. The agency also noted that its evaluation “found that the new products, including the 11 mg product authorized today, contain lower levels of most harmful and potentially harmful constituents (HPHCs)” than other oral and smokeless tobacco products.
The measurement literature agrees, from both directions of the funding question.
Industry-funded, finds a reasonably consistent label. Lunell et al. (2020, Nicotine & Tobacco Research, doi 10.1093/ntr/ntaa068) measured ZYN at 3, 6 and 8 mg: measured contents of 2.86, 5.89 and 7.52 mg against labels of 3, 6 and 8, and extracted fractions of 55.9%, 59.1% and 50.4%. The 8 mg pouch delivered 3.79 mg — under half its label. Funding, stated plainly: “The present study was funded by Swedish Match AB, Stockholm, Sweden.” Three of the four authors had Swedish Match ties, including an employee. (I could not retrieve the full declaration-of-interests text verbatim; the fetch layer refused it on two attempts. The funding line is quoted exactly.)
Regulator-funded, finds the label does not predict delivery. Mallock-Ohnesorg et al. (2024, Frontiers in Pharmacology 15:1392027) tested 6, 20 and 30 mg pouches. Extraction varied by product, not by dose: 24% from the 20 mg pouch and 52% from the 30 mg one. “Relative bioavailability in relation to the 6 mg (analyzed 4.8 mg) pouch was 70% for the 20 mg (analyzed 16.3 mg) pouch” and 165% for the 30 mg. The authors’ conclusion is the sentence to remember: results “also speak against a linear relationship between nicotine delivery and nicotine content in the pouch”. Funding: “The study was funded by intermural funding from the German Federal Institute for Risk Assessment (BfR)”, grant BfR-CPS-08-60-0102-02.P606, with the authors declaring no commercial or financial relationships.
Note what that pairing means. The study paid for by the manufacturer found the labels broadly orderly; the study paid for by a regulator found that a pouch with three and a bit times the nicotine delivered less than the small one, relatively speaking. Both funding statements are on the record and both belong in any honest reading.
Publicly funded, finds the labels run low. Rantaša and Finšgar (Analyst, doi 10.1039/d6an00153j, first published 9 April 2026) analysed 26 pouches and reported that “The determined nicotine content in NPs deviated up to −52.9% from that declared by the manufacturers” — every deviation negative, averaging −28.8%. Funded by the Slovenian Research Agency and the European Regional Development Fund; “The authors declare no conflict of interest.” The paper does not link deviation size to declared strength, so I am not going to claim the error is worse at the top of the ladder.
Put together: the number on a 9 mg can is an upper bound on what is in the pouch, and what reaches you is some unpredictable fraction of that. Anyone treating 9 mg as three times 3 mg is doing arithmetic the evidence does not support, and cigarette-equivalence claims inherit all of it and add more.
What a regulator actually says about strength — and what it does not
BfR’s 2022 opinion is the most substantial regulatory document on pouch strength anywhere, and it holds a surprise for anyone expecting this tier to be singled out. First, the context. In BfR’s sample of 44 pouches bought online, “The median weight per pouch was 0.6 g and the nicotine content per pouch was 9.48 mg”, with a range from 1.79 mg to 47.5 mg. The median pouch in that sample was a 9.48 mg pouch. On that evidence the 9–11 mg band was the middle of the market, not its extreme.
Second, BfR named an upper limit of its own, and it is above this tier:
“Based on data for the 30 mg product, the blood concentration that is achievable” “with a comparably well-reabsorbed 16.6 mg product was calculated.” “The BfR defined this 16.6 mg/pouch as the applicable upper limit based on the acute toxicity of nicotine.”
The reasoning was that a 16.6 mg pouch would produce a blood concentration of about 16.2 ng/ml, which BfR describes as “comparable with the blood concentration achieved after cigarette consumption”. A 9 mg and an 11 mg pouch both sit below that line.
Third, and this is where I have to report against the grain: BfR’s findings on harm do not distinguish this tier. Its oral mucosa result reads “all nicotine pouch users reported oral mucosa irritation ranging from moderate (0–20 mg nicotine) to severe (30 mg)” — a 9 mg pouch and a 3 mg pouch fall in the same bucket. And its discussion of the acute reference dose cuts against the whole category rather than the top of it: BfR notes that if the EFSA acute reference dose of 0.0008 mg/kg bodyweight “is used, nicotine pouches containing all nicotine quantities presented in this report will be withdrawn from the market”, observing that even a 3 mg pouch produces a median heart-rate increase of 8.5 beats, comparable to the effect the reference dose is built on.
So the honest summary is this: regulators have not identified the 9–11 mg band as a distinct danger zone. What they have identified is a labelling problem, a category-wide question about nicotine dose, and one calculated ceiling at 16.6 mg per pouch that this tier sits under.
Chemical-labelling law does mark a line in this region, though on a per-gram basis: BfR notes that products at 2.5 mg/g or more must carry the GHS07 pictogram, and “those exceeding 16.7 mg/g must bear pictogram GHS06 (skull and crossbones, signal word: ‘Danger’)”. Beware the near-collision of numbers here — BfR’s acute-toxicity ceiling is 16.6 mg per pouch, its skull-and-crossbones threshold is 16.7 mg per gram, and Finland’s statutory cap is 16.6 mg per gram. Three different quantities, nearly identical digits.
The modified-risk orders stop at 6 mg
One last asymmetry, of the sort that gets flattened in summaries. On 30 June 2026 the FDA authorised 20 ZYN products to carry a specific modified-risk claim — that using them instead of cigarettes lowers the risk of certain named diseases. The press release describes the covered products as ten flavours “each with two nicotine strengths (3 milligram and 6 milligram)”. The order letter’s appendix enumerates all 20 by application number, every one of them 3 mg or 6 mg per pouch. ZYN ULTRA does not appear in the document, and at the time it was not authorised for sale at all — that came seven weeks later.
FDA’s own limiting language is worth carrying across: “An order permitting the sale of a modified risk tobacco product (MRTP) refers to specific products, not an entire class of tobacco products”, and “There is no safe tobacco product, and those who do not use tobacco products should not start.” Whatever the modified-risk orders say, they say it about the 3 mg and 6 mg products. Nothing about them extends to the 9–11 mg tier.
Who this tier is for
No regulator anywhere offers guidance on which strength a new user should pick — that is a confirmed negative, not an oversight. The makers that do give guidance agree on who they are addressing: Nordic Spirit frames its starter formats for “existing adult nicotine users who are new to using nicotine pouches”, ZYN UK points newcomers at its 1.5 mg and 3 mg ranges, and VELO Sweden addresses someone who already uses pouches.
Read against that, this band is plainly not an entry point. It is the top of the American ladder, the Danish legal ceiling and a mid-table rung in Britain — which tells you more about regulators than about pouches. Stepping up from 6 mg means crossing the widest gap on the US ladder with nothing in between, and stepping back down is harder than stepping up. If one turns out to be too much, take it out.
FAQ
Is 9 mg strong?
By US standards it is the top of the ladder; by British or Swedish standards it is mid-range; in Denmark it is the legal maximum. “Strong” is a statement about a market, not about a pouch. On BfR’s 2022 market sample, 9.48 mg was the median.
How much nicotine does a 9 mg pouch actually give you?
Less than 9 mg, by an amount nobody can predict from the label. The nearest measured comparison is Lunell’s ZYN 8 mg, which released 3.79 mg — 50.4% of its measured content. A regulator-funded study found extraction varied from 24% to 52% across products with no consistent relationship to the stated dose.
Why can I buy an 11 mg pouch in the US but not in Denmark?
Because the two regulators took different routes. The US has no statutory cap and approves products individually; Denmark legislated a flat 9.0 mg per pouch ceiling, effective 1 July 2025.
Does “9 mg” mean per pouch or per gram?
It depends on the brand, and most do not say. ZYN ULTRA’s 9 mg is per pouch. Nordic Spirit’s “9 mg per gram” products contain 3, 4 or 6 mg per pouch. BfR found the basis clearly declared on only about a third of the pouches it examined.
Are 9–11 mg pouches more dangerous than 6 mg ones?
No regulator has said so. BfR’s oral-irritation finding groups everything from 0 to 20 mg together, and its acute-reference-dose argument applies to the whole category rather than the top of it. BfR’s own calculated acute-toxicity ceiling is 16.6 mg per pouch, above this tier. None of which makes any of these products safe — nicotine is addictive and no nicotine product is safe at any strength.
Do the ZYN modified-risk claims cover ULTRA?
No. The 20 products covered by FDA’s 30 June 2026 modified-risk orders are all 3 mg or 6 mg, enumerated individually in the order letter. ULTRA was not authorised for sale until 21 August 2026.
Sources
- FDA, Nicotine Pouch Products Authorized by the FDA. Content current as of 21 August 2026.
- FDA, FDA Authorizes 11 New Nicotine Pouches, 21 August 2026.
- FDA, FDA Authorizes 20 ZYN Nicotine Pouches to be Marketed with a Specific Modified Risk Claim, 30 June 2026, and the modified risk order letter and Appendix A.
- Indenrigs- og Sundhedsministeriet, Bekendtgørelse nr. 249 af 4. marts 2025 om grænseværdier for nikotinindhold i tobakssurrogater, §§ 1–3.
- Ministerstvo zdravotnictví, Vyhláška č. 141/2023 Sb. o nikotinových sáčcích bez obsahu tabáku, §§ 2(4), 2(5), 10.
- Dziennik Ustaw 2025 poz. 799, ustawa z dnia 21 maja 2025 r., art. 11hb.
- Tobacco and Vapes Act 2026 c.18, s.96 — a regulation-making power, unexercised as at 9 October 2026.
- Bundesinstitut für Risikobewertung, Health risk assessment of nicotine pouches, updated BfR Opinion no. 023/2022, 7 October 2022.
- Lunell E, Fagerström K, Hughes J, Pendrill R, “Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff”, Nicotine & Tobacco Research, doi 10.1093/ntr/ntaa068. Funded by Swedish Match AB.
- Mallock-Ohnesorg N et al., “Oral nicotine pouches with an aftertaste?”, Frontiers in Pharmacology 15:1392027, 22 May 2024. Funded by the German Federal Institute for Risk Assessment.
- Rantaša M, Finšgar M, Analyst, doi 10.1039/d6an00153j, first published 9 April 2026. Funded by the Slovenian Research Agency and the European Regional Development Fund.
- Nordic Spirit FAQ; ZYN US FAQ; ZYN UK strengths page; VELO US FAQ; VELO Denmark product listing; VELO Sweden; Rogue product range. Manufacturer sources, read as such.
Last verified: 9 October 2026.